Broad Institute paper offers potential new framework for treating Huntington’s diseasenews2025-01-16T16:00:44+00:00January 16th, 2025|Endpoints News|
OS Therapies plots expedited approval for osteosarcoma drug after Phase 2 winnews2025-01-15T12:40:44+00:00January 15th, 2025|Endpoints News|
Regenxbio sells Hunter syndrome license with FDA filing underwaynews2025-01-14T16:37:58+00:00January 14th, 2025|Endpoints News|
Anavex reports long-term Alzheimer’s data for drug with history of scrutinynews2025-01-14T15:51:24+00:00January 14th, 2025|Endpoints News|
Daiichi Sankyo brings Glycotope antibody in-house for $132.5Mnews2025-01-14T12:07:47+00:00January 14th, 2025|Endpoints News|
Biohaven’s protein degrader is promising in early IgAN trial, heads straight to Phase 3news2025-01-14T11:59:02+00:00January 14th, 2025|Endpoints News|
AbbVie partners with Simcere Pharma unit to develop myeloma drugnews2025-01-13T16:46:11+00:00January 13th, 2025|Endpoints News|
Hengrui and Kailera’s injected incretin posts best-in-class obesity data in Phase 2 trialnews2025-01-13T15:55:34+00:00January 13th, 2025|Endpoints News|
Gilead taps into STAT6 space via $250M deal with Leo Pharmanews2025-01-13T11:58:44+00:00January 13th, 2025|Endpoints News|
Regor’s obesity pill posts muted weight loss in Phase 2a, enters new trialnews2025-01-13T11:06:52+00:00January 13th, 2025|Endpoints News|
